Taysha Gene Therapies Operating Expenses 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Taysha Gene Therapies operating expenses from 2020 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Taysha Gene Therapies Operating Expenses 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Taysha Gene Therapies operating expenses from 2020 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$20.1B
Dr Reddy's Laboratories (RDY)	$13.1B
BridgeBio Pharma (BBIO)	$5B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.8B
Personalis (PSNL)	$315M
Assembly Biosciences (ASMB)	$117M
Acasti Pharma (ACST)	$28M
Sol-Gel Technologies (SLGL)	$20M
Evoke Pharma (EVOK)	$4M
Teligent (TLGT)	$0M